Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients

Journal of Gastrointestinal Surgery

Volumn 12, Issue 10, 2008, Pages 1738-1744

  Appau, Kweku A ^a   Fazio, Victor W ^a   Shen, Bo ^a   Church, James M ^a   Lashner, Bret ^a   Remzi, Feza ^a   Brzezinski, Aaron ^a   Strong, Scott A ^a   Hammel, Jeffrey ^a   Kiran, Ravi P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Abscess; Anastomotic leak; Crohn's disease; Ileocolonic resection; Infliximab; Postoperative complications; Readmissions; Sepsis

Indexed keywords

ANTIINFLAMMATORY AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY;

ADULT; COHORT ANALYSIS; COLON; COLON RESECTION; CONFERENCE PAPER; CROHN DISEASE; FEMALE; HUMAN; ILEUM; MALE; MIDDLE AGED; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; TIME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COLECTOMY; COLON; CROHN DISEASE; FEMALE; HUMANS; ILEUM; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 52549086464     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0646-0     Document Type: Conference Paper

References (28)

1. RA van Hogezand 1994 Medical management of patients with difficult-to-treat inflammatory bowel disease Neth J Med. 45 2 55 59
2. J Rasenack W Kreisel 1991 Conservative therapy of ulcerative colitis and Crohn disease Fortschr Med. 109 11 245 247
3. SB Hanauer 1999 Medical therapy for Crohn's disease Curr Opin Gastroenterol. 15 4 308 314
4. SB Hanauer 2007 Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down" Rev Gastroenterol Disord. 7 Suppl 2 S17 22
5. B Oldenburg D Hommes 2007 Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 23 4 395 399
6. MJ Frikker MM Segall 1983 The resectional reoperation rate for Crohn's disease in a general community hospital Dis Colon Rectum. 26 5 305 309
7. SW Polle JF Slors GJ Weverling DJ Gouma DW Hommes WA Bemelman 2005 Recurrence after segmental resection for colonic Crohn's disease Br J Surg. 92 9 1143 1149
8. DB Sachar 1996 Maintenance strategies in Crohn's disease Hospital Practice (1995) 31 1 99 106
9. JJ Murray DJ Schoetz Jr FW Nugent JA Coller MC Veidenheimer 1984 Surgical management of Crohn's disease involving the duodenum Am J Surg. 147 1 58 65
10. SR Targan SB Hanauer SJ van Deventer L Mayer DH Present T Braakman 1997 A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group N Engl J Med. 337 15 1029 1035
11. A Kornbluth 1998 Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference Inflamm Bowel Dis. 4 4 328 329
12. SB Hanauer BG Feagan GR Lichtenstein LF Mayer S Schreiber JF Colombel 2002 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet. 359 9317 1541 1549
13. BG Feagan S Yan M Bala W Bao GR Lichtenstein 2003 The effects of infliximab maintenance therapy on health-related quality of life Am J Gastroenterol. 98 10 2232 2238
14. T Andus EF Stange D Hoffler B Keller-Stanislawski 2003 Suspected cases of severe side effects after infliximab (Remicade) in Germany Med Klin (Munich). 98 8 429 436
15. RA Hansen G Gartlehner GE Powell RS Sandler 2007 Serious adverse events with infliximab: analysis of spontaneously reported adverse events Clin Gastroenterol Hepatol. 5 6 729 735
16. CM Byrne MJ Solomon JM Young W Selby JD Harrison 2007 Patient preferences between surgical and medical treatment in Crohn's disease Dis Colon Rectum. 50 5 586 597
17. J Chang L Girgis 2007 Clinical use of anti-TNF-alpha biological agents-a guide for GPs Aust Fam Physician. 36 12 1035 1038
18. CR Selvasekar RR Cima DW Larson EJ Dozois JR Harrington WS Harmsen 2007 Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis J Am Coll Surg. 204 5 956 962
19. IJ Mor JD Vogel A da Luz Moreira B Shen J Hammel FH Remzi 2008 Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy Dis Colon Rectum 51 8 1202 1207
20. JF Colombel EV Loftus Jr WJ Tremaine JH Pemberton BG Wolff T Young-Fadok 2004 Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy Am J Gastroenterol. 99 5 878 883
21. L Marchal G D'Haens G Van Assche S Vermeire M Noman M Ferrante 2004 The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study Aliment Pharmacol Ther. 19 7 749 754
22. F Cornillie D Shealy G D'Haens K Geboes G Van Assche J Ceuppens 2001 Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease Aliment Pharmacol Ther. 15 4 463 473
23. JM Bratcher BI Korelitz 2006 Toxicity of infliximab in the course of treatment of Crohn's disease Expert Opin Drug Saf. 5 1 9 16
24. JG Reddy EV Loftus Jr 2006 Safety of infliximab and other biologic agents in the inflammatory bowel diseases Gastroenterol Clin North Am. 35 4 837 855
25. GK Weston-Petrides RE Lovegrove HS Tilney AG Heriot RJ Nicholls NJ Mortensen 2008 Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy Arch Surg. 143 4 406 412
26. MC Hochberg MG Lebwohl SE Plevy KF Hobbs DE Yocum 2005 The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Semin Arthritis Rheum. 34 6 819 836
27. MN Kalkay I Cordoba D Plevy 1975 The nonreflux determinant of esophagitis Am J Gastroenterol. 63 2 135 146
28. SE Plevy CJ Landers J Prehn NM Carramanzana RL Deem D Shealy 1997 A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease J Immunol. 159 12 6276 6282